Key points
- Durvalumab (Imfinzi) is an immunotherapy drug: it releases the brake the cancer has put on the immune system [1].
- It is used for lung cancer (before and after surgery, after chemoradiotherapy and in disease that has spread), bile duct, liver, womb, bladder and stomach cancer [1].
- It is given as a 60-minute drip, usually every 3 or 4 weeks [1].
- The most common side effects: cough, lung inflammation, tiredness, cold-like infections, shortness of breath and skin rash [1].
- The main risk is immune-related inflammation, which can affect any organ, even after treatment ends; report any new symptom early [1] (immunotherapy side effects).
- Women should avoid pregnancy during treatment and for 3 months after the last dose, and should not breastfeed [1].
What is this drug and how does it work?
For physicians
Durvalumab (brand name Imfinzi) is a human IgG1 kappa monoclonal antibody from the group of immunotherapy drugs called immune checkpoint inhibitors [1].
The protein PD-L1 may be expressed on tumour cells and surrounding immune cells in response to inflammatory signals. By binding PD-1 and CD80 (B7.1), PD-L1 suppresses T-cell activity and activation and reduces their cytotoxicity, proliferation and cytokine production. Durvalumab binds PD-L1 and blocks its interaction with PD-1 and CD80, releasing the inhibition of the immune response [1].
Put simply, durvalumab releases the “brake” the tumour has put on the immune system. This immune activation sometimes makes the immune system attack healthy tissues too, which is the origin of immune-related adverse reactions [1].
Which cancers is it used for?
In endometrial cancer, patients are selected by mismatch repair deficiency (dMMR) in a tumour sample [1]. Not every patient with these cancers is a candidate for this drug; the final decision rests with the treatment team.
Your doctor may prescribe this drug for:
- Non-small cell lung cancer that can be removed by surgery [1]
- Stage III non-small cell lung cancer that cannot be removed by surgery [1]
- Non-small cell lung cancer that has spread [1]
- Limited-stage small cell lung cancer [1]
- Extensive-stage small cell lung cancer [1]
- Advanced or spread bile duct cancer [1]
- Hepatocellular carcinoma that cannot be removed by surgery [1]
- Advanced or recurrent endometrial cancer with dMMR [1]
- High-risk non-muscle-invasive bladder cancer (no previous BCG) [1]
- Muscle-invasive bladder cancer [1]
- Stomach or gastro-oesophageal junction adenocarcinoma that can be removed by surgery [1]
- Hepatocellular carcinoma with chemoembolisation (not an FDA-labelled use) [1]
Whether it suits you depends on the type and stage of your cancer and your test results. Details of each use are in the section for doctors.
For physicians
| Cancer | Conditions of use |
|---|---|
| Resectable non-small cell lung cancer | With platinum-based chemotherapy before surgery, then as monotherapy after surgery; tumours of 4 cm or larger and/or node-positive, without known EGFR mutations or ALK rearrangements [1] |
| Unresectable stage III non-small cell lung cancer | Monotherapy in patients without progression after concurrent platinum-based chemoradiotherapy; up to 12 months [1] |
| Metastatic non-small cell lung cancer | With tremelimumab and platinum-based chemotherapy, without sensitising EGFR mutations or ALK alterations [1] |
| Limited-stage small cell lung cancer | Monotherapy after concurrent platinum-based chemoradiotherapy in patients without progression; up to 24 months [1] |
| Extensive-stage small cell lung cancer | First line with etoposide and carboplatin or cisplatin, then monotherapy [1] |
| Advanced or metastatic biliary tract cancer | With gemcitabine and cisplatin, then monotherapy [1] |
| Unresectable hepatocellular carcinoma | With a single dose of tremelimumab (STRIDE regimen), then monotherapy [1] |
| Advanced or recurrent dMMR endometrial cancer | With carboplatin and paclitaxel, then monotherapy [1] |
| High-risk non-muscle-invasive bladder cancer (BCG-naive) | With intravesical BCG (induction and maintenance); up to 13 cycles [1] |
| Muscle-invasive bladder cancer | With gemcitabine and cisplatin before radical cystectomy, then as monotherapy after surgery; up to 8 cycles after surgery [1] |
| Resectable gastric or gastro-oesophageal junction adenocarcinoma | With FLOT before and after surgery, then monotherapy [1] |
| Hepatocellular carcinoma with chemoembolisation (not an FDA-labelled use) | With bevacizumab and TACE; this use is not among the FDA label indications [1] |
The table is based on the FDA label (revised August 2026); indications in other countries may differ. The last row is not an FDA-labelled use.
| Cancer | Key evidence |
|---|---|
| Resectable non-small cell lung cancer | AEGEAN trial: pathological complete response 17.2% vs 4.3% and hazard ratio for events 0.68 [1, 2] |
| Unresectable stage III non-small cell lung cancer | PACIFIC trial: 5-year overall survival 42.9% vs 33.4% [3] |
| Metastatic non-small cell lung cancer | POSEIDON trial: median overall survival 14.0 vs 11.7 months [1] |
| Limited-stage small cell lung cancer | ADRIATIC trial: median overall survival 55.9 vs 33.4 months compared with placebo [1, 4] |
| Extensive-stage small cell lung cancer | CASPIAN trial: median overall survival 13.0 vs 10.3 months [1, 5] |
| Advanced or metastatic biliary tract cancer | TOPAZ-1 trial: median overall survival 12.8 vs 11.5 months (hazard ratio 0.80) [1, 6] |
| Unresectable hepatocellular carcinoma | HIMALAYA trial: median overall survival 16.4 vs 13.8 months compared with sorafenib [1, 7] |
| Advanced or recurrent dMMR endometrial cancer | DUO-E trial: hazard ratio for progression or death 0.42 in the dMMR subgroup [1, 8] |
| High-risk non-muscle-invasive bladder cancer (BCG-naive) | POTOMAC trial: hazard ratio for recurrence or death 0.68 [1] |
| Muscle-invasive bladder cancer | NIAGARA trial: hazard ratio for events 0.68 and for death 0.75 [1, 9] |
| Resectable gastric or gastro-oesophageal junction adenocarcinoma | MATTERHORN trial: hazard ratio for events 0.71 and, at the final analysis, for death 0.78 [1, 10] |
| Hepatocellular carcinoma with chemoembolisation (not an FDA-labelled use) | EMERALD-1 trial: median progression-free survival 15.0 vs 8.2 months [11] |
How it is taken and dosing
Show detailsHide
Treatment regimens and doses: index11 regimens
Durvalumab is given at a treatment centre as an intravenous infusion over 60 minutes [1]. Depending on the cancer and the regimen, infusions are usually given every 2, 3 or 4 weeks [1].
How long treatment lasts depends on the cancer; for example, after chemoradiotherapy in stage III non-small cell lung cancer up to 12 months, and in limited-stage small cell lung cancer up to 24 months, while in metastatic disease it continues until the disease progresses or a side effect cannot be tolerated [1]. In treatment before and after surgery (lung, bladder, stomach), the number of cycles is set in advance [1].
Before starting and regularly during treatment, liver enzymes, creatinine and thyroid function are checked [1].
- Before starting: baseline liver enzymes, creatinine and thyroid function; confirm pregnancy status in women who could become pregnant; in endometrial cancer, determine dMMR with an approved test [1].
- Infusion: after dilution in 0.9% saline or 5% dextrose (final concentration 1 to 15 mg/mL), over 60 minutes with a 0.2 or 0.22 µm in-line filter and through a separate line. Premedication is not routinely needed; after a grade 1 to 2 infusion reaction, consider premedication for later doses. On shared days, durvalumab before chemotherapy or BCG and after tremelimumab [1].
- Monitoring during treatment: liver enzymes, creatinine and thyroid function periodically; blood glucose (type 1 diabetes); symptoms of pneumonitis, colitis, adrenal insufficiency and hypophysitis; weigh the patient before each infusion in the POSEIDON regimen [1].
- Dose modification: no dose reductions are recommended; only withholding or permanent discontinuation (details in “Dose modification for immune-related adverse reactions” after the regimens) [1].
- Weight below 30 kg: the dose is weight-based; the amount for each regimen is given in that regimen's note [1].
For physicians
Regimens and dosing in lung cancer (FDA label, revised 08/2026)
Resectable NSCLC (before and after surgery)
Tumour of 4 cm or larger and/or N+, without known EGFR/ALK
Tumour of 4 cm or larger and/or N+, without known EGFR/ALK [1]
Before prescribing: Shared safety points| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Neoadjuvant: up to 4 cycles | |||
| Durvalumab | 1500 mg | IV, 60-minute infusion | Day 1, every 3 weeks |
| Platinum-based chemotherapy | As per those drugs' labels | IV | Same day, after durvalumab |
| Adjuvant: up to 12 cycles | |||
| Durvalumab | 1500 mg | IV, 60-minute infusion | Day 1, every 4 weeks |
Weight below 30 kg: 20 mg/kg on the same schedule [1].
Unresectable stage III NSCLC (consolidation)
No progression after concurrent platinum-based chemoradiotherapyCycle length: 14 or 28 days
No progression after concurrent platinum-based chemoradiotherapy [1]
Before prescribing: Shared safety points| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Monotherapy | |||
| Durvalumab | 10 mg/kg or 1500 mg | IV, 60-minute infusion | 10 mg/kg every 2 weeks or 1500 mg every 4 weeks |
Weight below 30 kg: only 10 mg/kg every 2 weeks [1].
Metastatic NSCLC (POSEIDON regimen)
First line, without sensitising EGFR mutations or ALK alterations
First line, without sensitising EGFR mutations or ALK alterations [1]
Before prescribing: Shared safety points| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Induction: 4 cycles | |||
| Tremelimumab | 75 mg | IV, 60-minute infusion | Day 1, every 3 weeks (given first) |
| Durvalumab | 1500 mg | IV, 60-minute infusion | Day 1, every 3 weeks |
| Chemotherapy by histology | Non-squamous: carboplatin + nab-paclitaxel or carboplatin/cisplatin + pemetrexed; squamous: carboplatin + nab-paclitaxel or carboplatin/cisplatin + gemcitabine | IV | Day 1 (after durvalumab) |
| Maintenance (from cycle 5) | |||
| Durvalumab | 1500 mg | IV, 60-minute infusion | Every 4 weeks; ± pemetrexed every 4 weeks in non-squamous disease |
| Week 16 | |||
| Tremelimumab (fifth dose) | 75 mg | IV, 60-minute infusion | With the sixth durvalumab dose |
Cycle 1: tremelimumab over 60 minutes, then durvalumab over 60 minutes 1 to 2 hours later, then chemotherapy 1 to 2 hours later; if there was no infusion reaction in cycle 1, in later cycles durvalumab may follow tremelimumab immediately and chemotherapy may start 30 minutes after durvalumab. If fewer than 4 platinum cycles are given, the remaining tremelimumab doses (up to 5 in total) are given every 4 weeks after the platinum phase. Weight below 30 kg: durvalumab 20 mg/kg and tremelimumab 1 mg/kg [1].
Limited-stage SCLC (consolidation)
No progression after concurrent platinum-based chemoradiotherapyCycle length: 28 days
No progression after concurrent platinum-based chemoradiotherapy [1]
Before prescribing: Shared safety points| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Monotherapy | |||
| Durvalumab | 1500 mg | IV, 60-minute infusion | Day 1, every 4 weeks |
Weight below 30 kg: 20 mg/kg every 4 weeks [1].
Extensive-stage SCLC (CASPIAN regimen)
First line
First line [1]
Before prescribing: Shared safety points| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Induction: 4 cycles | |||
| Durvalumab | 1500 mg | IV, 60-minute infusion | Day 1, every 3 weeks |
| Etoposide + carboplatin or cisplatin | As per those drugs' labels | IV | After durvalumab |
| Maintenance | |||
| Durvalumab | 1500 mg | IV, 60-minute infusion | Every 4 weeks |
Weight below 30 kg: 20 mg/kg every 3 weeks with chemotherapy, then 10 mg/kg every 2 weeks [1].
Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.
Regimens and dosing in biliary, liver, gastric, endometrial and bladder cancer (FDA label, revised 08/2026)
Biliary tract cancer (TOPAZ-1 regimen)
Locally advanced or metastatic
Locally advanced or metastatic [1]
Before prescribing: Shared safety points| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Combination: up to 8 cycles | |||
| Durvalumab | 1500 mg | IV, 60-minute infusion | Day 1, every 3 weeks |
| Gemcitabine + cisplatin | As per those drugs' labels | IV | After durvalumab |
| Maintenance | |||
| Durvalumab | 1500 mg | IV, 60-minute infusion | Every 4 weeks |
Weight below 30 kg: 20 mg/kg [1].
Unresectable HCC (STRIDE regimen)
With a single dose of tremelimumabCycle length: 28 days
With a single dose of tremelimumab [1]
Before prescribing: Shared safety points| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Cycle 1 | |||
| Tremelimumab | 300 mg (single dose) | IV, 60-minute infusion | Day 1 of cycle 1 |
| Durvalumab | 1500 mg | IV, 60-minute infusion | Day 1 of cycle 1, after 60 minutes of observation |
| Continuation | |||
| Durvalumab | 1500 mg | IV, 60-minute infusion | Every 4 weeks |
Weight below 30 kg: tremelimumab 4 mg/kg and durvalumab 20 mg/kg [1].
dMMR endometrial cancer (DUO-E regimen)
Primary advanced or recurrent; dMMR by an approved test
Primary advanced or recurrent; dMMR by an approved test [1]
Before prescribing: Shared safety points| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Combination: 6 cycles | |||
| Durvalumab | 1120 mg | IV, 60-minute infusion | Day 1, every 3 weeks |
| Carboplatin + paclitaxel | As per those drugs' labels | IV | After durvalumab |
| Maintenance | |||
| Durvalumab | 1500 mg | IV, 60-minute infusion | Every 4 weeks |
Weight below 30 kg: 15 mg/kg in the combination phase, then 20 mg/kg [1].
High-risk non-muscle-invasive bladder cancer (POTOMAC regimen)
BCG-naiveCycle length: 28 days
BCG-naive [1]
Before prescribing: Shared safety points| Drug | Dose | Route | Schedule |
|---|---|---|---|
| 13 cycles | |||
| Durvalumab | 1500 mg | IV, 60-minute infusion | Every 4 weeks |
| BCG induction and maintenance | As per the BCG label | Intravesical | On shared days after durvalumab |
Weight below 30 kg: 20 mg/kg [1].
Muscle-invasive bladder cancer (NIAGARA regimen)
Before and after radical cystectomy
Before and after radical cystectomy [1]
Before prescribing: Shared safety points| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Neoadjuvant: 4 cycles | |||
| Durvalumab | 1500 mg | IV, 60-minute infusion | Day 1, every 3 weeks |
| Gemcitabine + cisplatin | As per those drugs' labels | IV | After durvalumab |
| Adjuvant: up to 8 cycles | |||
| Durvalumab | 1500 mg | IV, 60-minute infusion | Every 4 weeks |
Weight below 30 kg: 20 mg/kg [1].
Resectable gastric or GEJ adenocarcinoma (MATTERHORN regimen)
Before and after surgery with FLOTCycle length: 28 days
Before and after surgery with FLOT [1]
Before prescribing: Shared safety points| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Neoadjuvant: up to 2 cycles | |||
| Durvalumab | 1500 mg | IV, 60-minute infusion | Every 4 weeks |
| Before and after surgery | |||
| FLOT | As per the FLOT protocol | IV | Days 1 and 15 of each 4-week cycle |
| Adjuvant: up to 2 cycles with FLOT, then up to 10 cycles as monotherapy | |||
| Durvalumab | 1500 mg | IV, 60-minute infusion | Every 4 weeks |
Weight below 30 kg: 20 mg/kg [1].
Before prescribing, check each dose against the drug label, laboratory tests and the patient’s condition.
- Immune-related adverse reactions: grade 2 pneumonitis: withhold; grade 3 to 4: discontinue permanently. Grade 2 colitis: withhold; grade 3: withhold or discontinue (discontinue permanently in regimens with tremelimumab); grade 4: discontinue permanently. Hepatitis without tumour liver involvement: ALT/AST above 3 to 8 times ULN or bilirubin above 1.5 to 3 times: withhold; ALT/AST above 8 times or bilirubin above 3 times: discontinue permanently. Nephritis (grade 2 to 3 creatinine): withhold; grade 4: discontinue permanently. Grade 2 to 4 myocarditis: discontinue permanently. Grade 2 neurological toxicity: withhold; grade 3 to 4: discontinue permanently. Grade 1 to 2 infusion reaction: interrupt or slow the rate; grade 3 to 4: discontinue permanently. Inability to taper corticosteroids to prednisone 10 mg/day or less within 12 weeks: discontinue permanently [1].
- Kidney and liver: mild to moderate renal impairment (creatinine clearance 30 to 89 mL/min) or hepatic impairment (bilirubin up to 3 times ULN) has no clinically important effect on pharmacokinetics; the effect of severe impairment is unknown [1].
Side effects
Common side effects
The most common side effects:
- Tiredness, cough, shortness of breath, cold-like infections and skin rash [1].
- Lung inflammation, especially if it is given after chemoradiotherapy to the lung [1].
- An underactive thyroid (tiredness, feeling cold, weight gain), which is usually treated with thyroid tablets [1].
- When given with chemotherapy: nausea, diarrhoea, constipation, poor appetite, hair loss and numbness of the hands and feet [1].
- Report any new or worsening symptom early; it may be the first sign of an immune side effect [1].
For physicians
Common adverse reactions depend on the type of cancer and the partner drugs. Examples from the FDA label [1]:
- Monotherapy after chemoradiotherapy in lung cancer: cough 40%, pneumonitis or radiation pneumonitis 34%, fatigue 34%, upper respiratory tract infection 26%, dyspnoea 25% and rash 23%; hypothyroidism 12% vs 1.7% with placebo [1].
- Monotherapy in limited-stage small cell lung cancer (ADRIATIC trial, 262 patients): pneumonitis or radiation pneumonitis 38% and fatigue 21% [1].
- With gemcitabine and cisplatin in biliary tract cancer: fatigue, nausea, constipation, decreased appetite, abdominal pain, rash and pyrexia (each in 20% of patients or more) [1].
- With tremelimumab in hepatocellular carcinoma: rash, diarrhoea, fatigue, pruritus, musculoskeletal pain and abdominal pain (each in 20% of patients or more) [1].
- With FLOT in gastric cancer: diarrhoea, nausea, peripheral neuropathy, fatigue, alopecia, decreased appetite, rash, abdominal pain, vomiting, musculoskeletal pain, pyrexia and stomatitis (each in 20% of patients or more) [1].
Some of these reactions (such as alopecia or neuropathy) are seen with combination regimens. Patients should report any new or worsening symptom to the treatment team, as it may be a sign of an immune-related adverse reaction [1].
Serious side effects
Immunotherapy sometimes makes the immune system attack healthy organs too. These side effects can happen at any time, even after treatment has ended [1] (immunotherapy side effects):
- Lungs: a new cough, shortness of breath or chest pain [1].
- Liver: yellow skin or eyes, dark urine [1].
- Bowel: diarrhoea, abdominal pain or blood in the stool [1].
- Glands: severe tiredness, dizziness, severe headache, thirst and passing a lot of urine [1].
- Skin, kidneys, heart, nerves and eyes: rash or blisters, passing less urine, palpitations, muscle weakness, blurred vision [1].
- A reaction during the infusion and harm to an unborn baby [1].
For physicians
Durvalumab has no boxed warning, but its immune-related adverse reactions can be severe or fatal, can occur in any organ and at any time, and can appear even after treatment stops [1]. Frequencies in 1889 patients receiving monotherapy (unless stated otherwise) [1]:
- Pneumonitis: in PACIFIC (after chemoradiotherapy) 18.3% vs 12.8% with placebo; fatal in 1.1% and grade 3 in 2.7% [1].
- Hypothyroidism: 8.3%, often requiring long-term thyroid hormone replacement; hyperthyroidism: 2.1%; thyroiditis: 0.5% [1].
- Immune-mediated hepatitis: 2.8% (fatal in 0.2%); with tremelimumab in HCC: 7.5% [1].
- Colitis: 2%; with tremelimumab in HCC, immune-mediated colitis or diarrhoea: 6% [1].
- Immune-mediated dermatological reactions (rash or dermatitis): 1.8% [1].
- Adrenal insufficiency: 0.5%; nephritis: 0.5%; type 1 diabetes: below 0.1%; hypophysitis: below 0.1% [1].
- Immune-mediated pancreatitis: 2.3% with tremelimumab in HCC [1].
- Infusion-related reactions: 2.2% (grade 3: 0.3%) [1].
- Allogeneic stem cell transplantation: serious and sometimes fatal complications in patients receiving an allogeneic transplant before or after these drugs [1].
- Embryo-fetal toxicity: in animal studies, giving durvalumab to pregnant monkeys was associated with more premature delivery, fetal loss and early neonatal death [1].
Other rare immune-related adverse reactions listed in the label for prompt attention include aseptic meningitis, encephalitis, immune thrombocytopenia, myocarditis, haemolytic anaemia, myositis, uveitis, keratitis and myasthenia gravis [1].
When should I call my doctor?
Contact your treatment team straight away if you have any of these new or worsening symptoms [1]:
- Cough, shortness of breath or chest pain
- Diarrhoea or more frequent bowel movements, black tarry stools or stools with blood or mucus, severe abdominal pain
- Yellow skin or eyes, severe nausea or vomiting, pain on the right side of the abdomen, dark urine, bleeding or bruising easily
- A persistent or unusual headache, palpitations, extreme tiredness, unusual thirst or hunger, passing urine more often, dizziness or fainting, feeling cold
- Passing less urine, blood in the urine, swollen ankles
- Rash, itching, blistering or peeling skin, painful sores in the mouth, nose, throat or genital area
- Upper abdominal pain with severe nausea or vomiting (possible pancreatitis)
- An irregular heartbeat, confusion, a stiff neck, balance problems, numbness or weakness of the arms or legs, double or blurred vision, severe muscle pain or weakness
- During or after an infusion: chills, itching, flushing, wheezing, dizziness, fever, back or neck pain
In severe cases (such as severe shortness of breath, chest pain or reduced consciousness), call your local emergency number.
Interactions, pregnancy and precautions
Drug interactions: the FDA label for durvalumab has no section on drug interactions [1]; even so, tell your doctor the full list of your prescription and over-the-counter medicines, vitamins and herbal supplements [1].
Tell your doctor before starting if you have: an autoimmune disease (such as Crohn disease, ulcerative colitis or lupus), had an organ or corneal transplant, had an allogeneic stem cell transplant, had chest radiotherapy, or have a nerve disease such as myasthenia gravis or Guillain-Barré syndrome [1].
Pregnancy and contraception: a pregnancy test is done before treatment. Women who could become pregnant should use effective contraception during treatment and for 3 months after the last dose; for the partner drugs (such as chemotherapy) the period needed may differ [1].
Breastfeeding: do not breastfeed during treatment and for 3 months after the last dose [1].
Vaccines: the FDA label gives no specific advice about vaccination during treatment [1]; talk to your treatment team before any vaccine.
Missed appointment: if you miss an infusion, contact your treatment team as soon as possible to rearrange it [1].
Older adults: the main studies reported no overall clinically important difference in safety or effectiveness between patients aged 65 and over and younger patients [1].
Children: the safety and effectiveness of durvalumab in children have not been established [1].
Frequently asked questions
Is durvalumab chemotherapy?
No. Durvalumab is an immunotherapy antibody that removes the brake on the immune response by blocking PD-L1 [1]. In some cancers it is given with chemotherapy, for example with gemcitabine and cisplatin in bile duct cancer [1].
Why is durvalumab given after chemoradiotherapy for lung cancer?
Does this drug make your hair fall out?
How long does each infusion take?
Can side effects appear after treatment has ended?
Yes. Immune-related side effects can appear at any time during treatment or even after it ends [1]. If you notice a new symptom after treatment has ended, tell your doctor that you have had durvalumab.
Scientific evidence
Show detailsHide
Key studies
7 itemsFive-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
Related cancer types
Treatment regimens (physicians)
References
11 referencesShow all references, 10 with a study cardClose the reference list
Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.
- 1IMFINZI (durvalumab) injection, for intravenous use: Prescribing InformationSource Back to text: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139
- 2Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
- 3Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- 4Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
- 5Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- 6Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
- 7Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
- 8Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
- 9Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
- 10Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
- 11Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
This page is based on reputable scientific sources and was last updated on 27 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.
Printed from the website; the full and up-to-date version: https://drdabiri.com/en/drugs/durvalumab/
